Corneal Thinning During Topical Bevacizumab Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00515684
Recruitment Status : Withdrawn (Side effect can increase the risk of the research)
First Posted : August 14, 2007
Last Update Posted : May 1, 2015
Information provided by:
Yonsei University

Brief Summary:
The purpose of this study is to determine whether topical bevacizumab is safe or not when used in corneal neovascularization for long term period.

Condition or disease Intervention/treatment Phase
Corneal Neovascularization Drug: bevacizumab (Avastin) Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Study Start Date : May 2007
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All

Inclusion Criteria:

  • clinical diagnosis of corneal neovascularization
  • must be able to apply eyedrop

Exclusion Criteria:

  • have active keratitis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00515684

Korea, Republic of
Severance hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Yonsei University
Principal Investigator: Sang Woo Kim, M.D. Severance hospital, Seoul , Korea Identifier: NCT00515684     History of Changes
Other Study ID Numbers: 4-2006-0234
First Posted: August 14, 2007    Key Record Dates
Last Update Posted: May 1, 2015
Last Verified: April 2015

Additional relevant MeSH terms:
Neovascularization, Pathologic
Corneal Neovascularization
Pathologic Processes
Corneal Diseases
Eye Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents